Physician profile
Scott Griffith
NPI 1124035290
$3,357.10
in general payments reported to CMS, 2019-2025
24 companies · $427 in 2025
The $427 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $759 · 2020: $431 · 2021: $304 · 2022: $481 · 2023: $476 · 2024: $478 · 2025: $427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,381.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $604.88 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $513.52 | 2019-2024 | Mounjaro, Jardiance |
| Amgen INC. | $443.00 | 2019-2025 | Repatha, Repatha, Otezla |
| Amarin Pharma, INC. | $395.20 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $310.81 | 2019-2025 | Farxiga, Airsupra |
| Corcept Therapeutics | $201.98 | 2024-2025 | Korlym |
| Kowa Pharmaceuticals America, INC. | $187.64 | 2019-2023 | Livalo |
| Azurity Pharmaceuticals, INC. | $86.62 | 2023-2024 | Horizant, Edarbi, Horizant |
| Exact Sciences Corporation | $85.19 | 2024-2025 | Cologuard Collection Kit |
| Eisai INC. | $73.89 | 2020-2021 | |
| Pfizer INC. | $69.41 | 2019-2024 | |
| Abbott Laboratories | $54.86 | 2019-2023 | Freestyle Libre 2 |
| Abbvie INC. | $54.36 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $46.19 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.86 | 2020-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $34.15 | 2020 | |
| Merck Sharp & Dohme LLC | $28.13 | 2019 | |
| Glaxosmithkline, LLC. | $24.38 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $21.71 | 2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $20.02 | 2019 | |
| Astellas Pharma US INC | $20.00 | 2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $17.77 | 2020 | |
| Dexcom, INC. | $15.43 | 2025 | Dexcom G6 Transmitter |
| Currax Pharmaceuticals LLC | $12.10 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Griffith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.